Business Context and Reporting Period
This Form 8-K Current Report from Inmune Bio, Inc. (INMB) covers the Annual Meeting of Stockholders held on June 1, 2023. The company is an emerging growth company incorporated in Nevada with principal executive offices in Boca Raton, Florida.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder actions. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is the approval by stockholders to amend the 2021 Stock Incentive Plan. The number of shares of common stock issuable under the plan was increased from 2,000,000 to 4,000,000 shares.
Outlook, Risks, and Management Commentary
Management commentary is limited to the reporting of voting results. No specific guidance, outlook, risks, or contingencies are detailed in this document. The company confirmed the ratification of Marcum LLP as its independent auditors for the fiscal year ending December 31, 2023.
Stockholder Voting Results
- Proposal One (Election of Directors): All six nominees (Raymond J. Tesi, J. Kelly Ganjei, Tim Schroeder, Scott Juda, Edgardo Baracchini, and Marcia Allen) were elected. Significant broker non-votes (5,920,593) were recorded for each nominee.
- Proposal Two (Ratification of Auditor): Marcum LLP was ratified with 13,197,733 votes for, 31,472 against, and 5,435 abstentions.
- Proposal Three (Stock Plan Amendment): The amendment to increase the share pool was approved with 6,585,434 votes for, 682,173 against, and 46,440 abstentions.
Investor Verification Checklist
- Verify the full terms of the Amended and Restated 2021 Stock Incentive Plan (Exhibit 10.1) to understand vesting schedules and eligibility.
- Review the 2023 Proxy Statement filed on April 21, 2023, for detailed background on the director nominees and the rationale for the stock plan increase.
- Confirm the impact of the increased share pool on potential future dilution for existing shareholders.
- Check subsequent filings for the company's latest financial position, as this 8-K contains no financial data.